Avient vs Eastman Chemical
AVNT and EMN side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVNT and EMN compare
Eastman Chemical is the larger company, worth 1.8 times as much as Avient ($7.4B against $4.1B).
On earnings, Eastman Chemical is cheaper: it trades at 12.0× trailing earnings, against 22.9× for Avient.
Avient grew revenue faster over the last twelve months (5.2% versus 0.27% for Eastman Chemical).
Eastman Chemical keeps more of each dollar of sales as profit, with a net margin of 6.9% compared with 5.3% at Avient.
Both pay dividends: Avient yields 2.5% and Eastman Chemical 5.2%.
Eastman Chemical scores higher on the StockData Score (16 against 13 for Avient), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVNT | EMN |
|---|---|---|
| Size and price | ||
| Market cap | $4.1B | $7.4B |
| Share price | $44.66 | $65.03 |
| Change, 1 year | 51.6% | 6.7% |
| Change, 5 years | −25.6% | −42.5% |
| Beta (5Y) | 1.33 | 1.10 |
| Employees | 9,000 | 13K |
| StockData Score | ||
| Total score | 13 | 16 (better) |
| Valuation score | 3 | 5 (better) |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 2 | 2 |
| Dividend score | 4 | 6 (better) |
| Valuation | ||
| P/E | 22.9× | 12.0× (better) |
| P/S | 1.2× | 0.8× (better) |
| P/B | 1.7× | 1.2× (better) |
| EV/EBITDA | 10.5× | – |
| P/FCF | 17.1× | 15.9× (better) |
| FCF yield | 5.8% | 6.3% (better) |
| Fair value | $54.00 | $92.79 |
| Margin of safety | 17.3% | 29.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.2% (better) | 0.27% |
| Revenue growth, 5Y average | 8.0% (better) | 0.65% |
| Net income growth (TTM) | 59.0% (better) | −13.3% |
| EPS growth (TTM) | 57.3% (better) | −12.3% |
| EPS growth, 5Y average | −9.3% | 3.2% (better) |
| Profitability | ||
| Gross margin | 31.7% (better) | 20.6% |
| Operating margin | 9.7% | – |
| Net margin | 5.3% | 6.9% (better) |
| FCF margin | 7.0% (better) | 5.2% |
| Return on equity | 7.5% | 10.4% (better) |
| Return on invested capital | 6.4% | – |
| Financial health | ||
| Debt / equity | 0.74 (better) | 0.83 |
| Net debt / EBITDA | 2.65 | – |
| Current ratio | 1.71 (better) | 1.57 |
| Altman Z-score | 1.59 | 2.13 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 2.5% | 5.2% (better) |
| Payout ratio | 55.7% | 61.1% |
| Years of dividend growth | 15 | 16 (better) |
| Dividend growth, 5Y average | 5.8% (better) | 4.5% |
| Shareholder yield | 2.5% | 5.2% (better) |
| Ownership | ||
| Held by institutions | 105% | 94.1% |
| Held by insiders | 0.83% | 0.83% |
| Insider net buying, 12 months | – | −$206K |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.7% | 4.9% |
Go deeper
- AVNT stock overview
- AVNT income statement
- AVNT valuation and score
- EMN stock overview
- EMN income statement
- EMN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.